Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10511
- Development stage
- Phase 1
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10511 is an orally administered, small molecule investigational drug developed by Jiangsu Hansoh Pharmaceutical Group and Shanghai Hansoh Biomedical. It is classified as a Category 1 innovative drug in China and is being developed for the treatment of hypertrophic cardiomyopathy (HCM). As of early 2024, it has entered Phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. The specific mechanism of action for HS-10511 has not been disclosed or defined publicly. The precise indication within HCM will be determined following completion of clinical research[1][2][3][4][5][8].
Beyond the preview
Go deeper on HS-10511.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10511.